1
www.OTCToolbox.com
2020AWARDSCONSUMER HEALTHCARE
INDUSTRY AWARDS
WINNERS
2020AWARDSCONSUMER HEALTHCARE
INDUSTRY AWARDS
The OTCToolbox Consumer Healthcare Industry (CHi) Awards for business development and innovation were presented on 27 February 2020 at the Networking & Awards Presentation Dinner during the OTCToolbox 2020 Consumer Healthcare BD&I Event
The best in business development and innovation
2
www.OTCToolbox.com
2020AWARDSCONSUMER HEALTHCARE
INDUSTRY AWARDS
The Winners
Congratulations to the winners of the OTCToolbox 2020 Consumer Healthcare Industry (CHi) Awards recognising the best in business development and innovation around the world.
Transaction of the YearWINNER Sanofi Consumer Healthcare – OTC Rights to Tamiflu in US This CHi Award honours the best transaction in 2019. Judges
were looking for a transaction – an acquisition, merger, licensing agreement, joint venture or strategic alliance – with the power to transform the company’s consumer healthcare presence.
Business Development Team of the YearWINNER Nestlé This CHi Award honours the best business development team in 2019.
Judges were looking for a business development team that announced and/or completed one or more transactions with the power to transform the consumer healthcare presence of the team’s company.
Innovation of the YearWINNER Vemedia Consumer Health’s Excilor Skintag Treatment This CHi Award honours the best consumer healthcare product
innovation in 2019.
Winners of the CHi Awards were decided by a panel of highly‑experienced executives in the consumer healthcare field. Many thanks to our panel of judges for giving us both their time and their expertise.
The CHi Awards are open to consumer healthcare/OTC companies from around the world. They cover a broad range of consumer healthcare/OTC products including: non‑prescription medicines; vitamins, minerals and supplements (VMS); self‑care medical devices; skin health products; and other consumer healthcare/OTC products.
Deborah WilkesFounder, Owner and Editorial DirectorOTCToolbox
Contents
The Winners 2
The Judges 3
Transaction of the Year 4
Business Development 5 Team of the Year
Innovation of the Year 6
The Awards Presentation 7
The OTCToolbox website produces publications and events that enable business developers and innovators in the consumer healthcare/OTC industry worldwide make well‑informed decisions.
OTCToolbox is part of Source Publishing Limited. Company registered in England No 06839664. Registered office: 54 Creynolds Lane, Solihull B90 4ER, United Kingdom. Tel: +44 121 314 8757. Email: [email protected].
No part of this publication may be copied, reproduced, stored in a retrieval system or transmitted in any form without prior permission from Source Publishing Ltd. © Source Publishing Ltd. All rights reserved.
Cover Image: © James Chipper / Rob Wilcockson / Stock.Adobe.com
3
www.OTCToolbox.com
2020AWARDSCONSUMER HEALTHCARE
INDUSTRY AWARDS
The Judges
Pierre-Antoine BodinPierre‑Antoine Bodin is Partner for Pharma & Healthcare at Roland Berger, with a special knowledge of OTC/consumer healthcare topics. Before joining Roland Berger in 2012, he spent eight years in various supply chain and marketing positions in pharmaceutical companies such as Pfizer and Johnson & Johnson.Awards judged – Transaction of the Year, Business Development Team of the Year
Chris BunnissChris Bunniss is Managing Director of Bunniss Associates and Marketing Director of The Marketing Centre. He spent 17 years at SSL International, including a period as Strategic Acquisitions Director.Awards judged – Transaction of the Year, Business Development Team of the Year
Keith GarrityKeith Garrity is Director of International Business Development at Ceuta International. Keith has more than 25 years of experience in the healthcare industry, with exposure to all trading channels from independent pharmacy to mass market retailers across many international platforms working with the Ceuta Global Alliance.Awards judged – Innovation of the Year
James HallJames Hall is a Regulatory Specialist at OTCexperts and Managing Director of Jenson R+. James has in excess of 25 years of regulatory experience in the OTC industry. His background covers a wide spectrum of areas including regulatory strategy and implementation, reclassifications, borderline products, promotional copy approval, medical devices and pharmacovigilance.Awards judged – Innovation of the Year
Mathias KäsebierMathias Käsebier is Senior Director of Bannert Manlik Consultants. Mathias is a former Director of the Americas for Boehringer Ingelheim Consumer Health Care and a former Chief Executive Officer and President of Heel USA. Awards judged – Transaction of the Year, Business Development Team of the Year
Bob MoranBob Moran is President of Plexus Ventures. Plexus has managed OTC mature product divestment projects for consumer healthcare companies around the globe including AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Novartis and Reckitt Benckiser. Plexus also helps clients to build their product portfolios through acquisitions and in‑licensing.Awards judged – Transaction of the Year, Business Development Team of the Year
Matthew OsterMatthew Oster is Industry Manager for Consumer Health at Euromonitor International. He manages research and analysis in 100 markets worldwide for a broad range of consumer healthcare products, including OTC medicines, vitamins and dietary supplements, weight management lines, and sports nutrition products. Awards judged – Innovation of the Year
Ros MundayRos Munday is a specialist OTC Consultant with experience gained over more than 20 years in the industry, including more than a decade at Sanofi. Ros operates across all disciplines from manufacturing through to consumer sales and marketing.Awards judged – Transaction of the Year, Business Development Team of the Year, Innovation of the Year
Jeremy PuttockJeremy Puttock is president of Healthy Brands. During his 30 years in the consumer healthcare industry, Jeremy’s positions have included Vice President Global Consumer Healthcare Franchises at Johnson & Johnson and Senior Vice President Global Non‑Prescription Medicines at Teva Pharmaceuticals. Awards judged – Transaction of the Year, Business Development Team of the Year, Innovation of the Year
Manfred ScheskeManfred Scheske is Chief Executive Officer and co‑founder of Infirst Healthcare. Manfred previously spent 25 years with GlaxoSmithKline’s Consumer Healthcare business where he led the European, North American and German businesses.Awards judged – Innovation of the Year
Ralf Sibbing Ralf Sibbing has multidisciplinary experience in the consumer healthcare/OTC field covering regulatory affairs, scientific and medical affairs, quality management and pharmaceutical consulting. He spent 24 years at Diapharm, including more than a decade as general manager or managing partner.Awards judged – Innovation of the Year
Andy Tisman Andy Tisman is Senior Director & Global Lead Consumer Health Strategy & Thought Leadership at IQVIA Consumer Health. Andy joined IQVIA in 2005 with a strong industry and consulting background including more than 15 years at SmithKline Beecham.Awards judged – Transaction of the Year, Business Development Team of the Year, Innovation of the Year
Deborah Wilkes Deborah Wilkes is Founder, Owner and Editorial Director of the OTCToolbox website. Deborah has more than 25 years of experience in analysing developments in the consumer healthcare/OTC market worldwide. She co‑founded the OTC bulletin and Generics bulletin newsletters, as well as creating OTC bulletin’s OTC Marketing Awards.Awards judged – Transaction of the Year, Business Development Team of the Year, Innovation of the Year
4
www.OTCToolbox.com
2020AWARDSCONSUMER HEALTHCARE
INDUSTRY AWARDS
Transaction of the Year
Sanofi Consumer Healthcare’s deal for exclusive OTC rights to Roche’s Tamiflu (oseltamivir) in the US wins the OTCToolbox CHi Award for Transaction of the Year. Judges said the transaction was a bold move with “huge potential”.
Sanofi announced in July 2019 that it had gained exclusive OTC rights to Roche’s Tamiflu (oseltamivir) for prevention and treatment of flu in the US. Tamiflu is currently a prescription medicine in the US where it is sold by Roche’s Genentech.
In the rest of the world, Roche will continue to market Tamiflu. Sanofi can have first negotiations for the rights to switch Tamiflu from prescription‑to‑OTC status in selected markets.
Commenting on the deal at the time, Alan Main, Sanofi’s Executive Vice President for Consumer Healthcare, said: “The US market is the largest OTC market in the world and a successful switch of Tamiflu to OTC status would support our global cough and cold strategy by expanding into flu with a sustainable point of difference in the market.”
Sanofi pointed out there was no effective OTC antiviral treatment for flu. The company said the existing OTC products only treated the symptoms of flu.
Main said that switching Tamiflu from prescription‑to‑OTC status would offer a “significant public health benefit” by “providing increased access to a safe and efficacious product for the prevention and treatment of flu”.
Impact of switching TamifluSpeaking in December 2019, Sanofi’s Chief Executive Officer Paul Hudson said two switches –
Tamiflu plus the erectile‑dysfunction drug Cialis (tadalafil) – had the potential to add EUR1 billion (USD1.1 billion) to Sanofi Consumer Healthcare’s top line.
Worldwide sales at Sanofi Consumer Healthcare reached EUR4.69 billion in 2019, down by 0.8% at constant currencies compared to 2018.
Financial details of the deal were not disclosed.New Zealand was the first country to switch Tamiflu from prescription‑to‑OTC status. A decade
later, Tamiflu remains a prescription medicine in most countries.
Comments from the judgesSix of the eight judges for the OTCToolbox CHi Award for Transaction of the Year ranked the
transaction first or second out of eight candidates.A transaction with “huge potential” was how Chris Bunniss of Bunniss Associates described the
deal. Noting that the transaction was “strategically very strong”, Bunniss praised Sanofi for “extracting a game changing switch from a prescription player”.
Pierre‑Antoine Bodin of Roland Berger commented that the deal was “quite a bold move” to create a new consumer healthcare category that had traditionally been prescription.
A third judge remarked that the transaction “could bring a new paradigm to the flu market, leading to market growth and driving growth for Sanofi”.
Rank Transaction Points (from a maximum of 40)
1 Sanofi’s acquisition of OTC rights to Tamiflu in US 28
2 Nestlé Health Science’s acquisition of Persona 26
3 Stada’s acquisition of Walmark 18
A successful switch of Tamiflu to OTC status will support our global cough and cold strategy by expanding into flu with a sustainable point of difference in the market, says Alan Main, Sanofi’s Executive Vice President for Consumer Healthcare
Eight judges evaluated eight candidates for this CHi Award
5
www.OTCToolbox.com
2020AWARDSCONSUMER HEALTHCARE
INDUSTRY AWARDS
Business Development Team of the Year
Nestlé captures the OTCToolbox CHi Award for Business Development Team of the Year thanks to a series of significant deals. Judges were particularly impressed by Nestlé Health Science’s move into personalisation.
Nestlé strengthened its consumer healthcare presence through a number of significant transactions in 2019, including deals involving personalisation, the microbiome and food‑allergy prevention.
In August 2019, Nestlé Health Science announced that it was expanding into personalised nutrition by acquiring the vitamins, minerals and supplements (VMS) company Persona for an undisclosed sum. The personalised nutrition service offered by Persona is available to consumers in the US through the website www.personanutrition.com. Nestlé Health Science said it planned to extend the service into further geographic areas in future.
Persona will be part of Nestlé Health Science’s Atrium VMS business which was acquired by Nestlé in 2018.
Personalised nutrition and wellnessCommenting on the opportunity offered by personalised nutrition and wellness, Nestlé said
the retail market – which includes dietary supplements, nutraceuticals and functional foods – was expanding “rapidly” and was expected to reach USD50 billion by 2025.
On 3 January 2020, Nestlé Health Science announced it was strengthening the presence of Atrium in personalised nutrition by acquiring LivingMatrix for an undisclosed sum.
Nestlé also recently announced a strategic collaboration with Caelus Health for the development of microbiome‑based food supplements, as well as entering into a partnership with the University of California San Diego Center for Microbiome Innovation (CMI) as it seeks to develop the “next generation of health‑promoting products”.
Also during 2019, Nestlé Health Science took a stake in Before Brands, the US‑based company that specialises in early childhood allergy prevention.
Comments from the judgesSix of the eight judges for the OTCToolbox CHi Award for Business Development Team of the
Year ranked Nestlé first or second out of the eight candidates.Jeremy Puttock of Healthy Brands said the Nestlé business development team had
made acquisitions that would “pave the way towards greater development and adoption of personalisation health and wellness solutions, driving the future growth of consumer healthcare/OTC and building a connection with practitioner and patient management systems”.
Mathias Käsebier of Bannert Manlik Consultants said the move into personalised nutrition – combined with the Atrium portfolio – might be a winning move. It would allow Nestlé to enter markets outside the US with a “compelling story instead of a difficult me‑too approach”, he added.
A third judge said the range of acquisitions and deals had the “potential to transform the Nestlé Health Science business and bring new paradigms to the OTC/self‑care market”.
Rank Business Development Team Points (from a maximum of 40)
1 Nestlé 31
2= HRA Pharma 26
2= Stada 26
Eight judges evaluated eight candidates for this CHi Award
Persona provides consumers with personalised vitamin packs
6
www.OTCToolbox.com
2020AWARDSCONSUMER HEALTHCARE
INDUSTRY AWARDS
Innovation of the Year
Vemedia Consumer Health’s Excilor Skintag Treatment picks up the OTCToolbox CHi Award for Innovation of the Year. Judges said the product was an “easy-to-use solution”.
“Innovation in product packaging and design has enabled a doctor’s office procedure to be conducted simply and safely at home,” was the verdict of Jeremy Puttock from Healthy Brands on Vemedia Consumer Health’s Excilor Skintag Treatment.
Puttock said the Excilor Skintag Treatment was an “easy‑to‑use solution” that would bring “additional sales and growth to the OTC market”.
Ralf Sibbing commented that Excilor Skintag Treatment was a “really innovative consumer healthcare product in a previously unoccupied sector”. He added that the product expanded the “excellent dermal competence of the Excilor umbrella brand”.
Another judge noted the product “met a largely unmet consumer need with safety, speed and minimum discomfort”.
Five of the nine judges for the OTCToolbox CHi Award for Innovation of the Year ranked Vemedia Consumer Health’s Excilor Skintag Treatment first or second out of the eight candidates.
How it worksEach pack of Excilor Skintag Treatment contains one applicator, three plaster‑discs, a quick
start guide and an information leaflet. Using the applicator, a plaster‑disc ligation device is placed over the stem of the skin tag
and covered by the plaster. The plaster‑disc cuts off the bloodstream to the skin tag, resulting in it drying out and dropping off the skin inside the plaster. Removal leaves a little red dot, but Vemedia Consumer Health said this disappeared after a week.
Claims on the product packaging state that Excilor Skintag Treatment provides “Effective removal within 6 days” as well as offering “Easy home use”. Straplines also highlight that the product is “Safe & hygienic” and causes “No pain”.
According to Vemedia Consumer Health, there are few dedicated skin tag treatments so self‑treaters turn to options such as homeopathy and even razors. “The skintag category is a clear white space with a huge potential to drive business for pharmacies and offer an effective solution for patients,” comments the company.
Vemedia Consumer Health said the Excilor Skintag Treatment had been launched initially in Belgium and the Netherlands in early 2019. During the course of 2019, the product was launched in a number of other countries including Italy, Portugal, Spain and the UK.
Recycling initiative is the runner-upThe runner‑up was RB’s Health & Nutrition Recycling Program. James Hall of Jenson R+ and
OTCexperts said developing methods to “help reduce waste to landfill and increase recycling is a global action and responsibility”. “The proactive and open approach by RB to address this is a step change for industry,” he added. “It is innovative in that this is an area which is not the norm and the foresight to approach a problem in this way should be applauded.”
Rank Innovation Points (from a maximum of 45)
1 Vemedia Consumer Health’s Excilor Skintag Treatment 25
2 RB’s Health & Nutrition Recycling Program 23
3 Beiersdorf’s Eucerin Anti‑Pigment 22
Claims on the product packaging state that Excilor Skintag Treatment provides “Effective removal within 6 days”
Nine judges evaluated eight candidates for this CHi Award
7
www.OTCToolbox.com
2020AWARDSCONSUMER HEALTHCARE
INDUSTRY AWARDS
The Awards Presentation
Transaction of the YearWINNER Sanofi Consumer Healthcare
– OTC Rights to Tamiflu in the US
Business Development Team of the Year
WINNER Nestlé
Innovation of the YearWINNER Vemedia Consumer Health’s
Excilor Skintag Treatment
Oliver Freichel, Vice President Business Development & Strategy at Sanofi Consumer Healthcare (pictured
centre right) and Markus Weiss, Head of Global BD&L C&C, Allergy / Rx‑to‑OTC Switches at Sanofi Consumer
Healthcare (centre left) were presented with the CHi Award by Deborah Wilkes of OTCToolbox (right)
and Andy Tisman of IQVIA Consumer Health (left)
Martin Hendrix, Head of Global Business Development and M&A at Nestlé Health Science (pictured centre),
collected the CHi Award from Deborah Wilkes of OTCToolbox (right) and Andy Tisman of
IQVIA Consumer Health (left)
An De Naeyer, Head of Innovation at Vemedia Consumer Health (pictured centre right), and
Yvan Vindevogel, Chairman of Vemedia Consumer Health (centre left), received the CHi Award from
Deborah Wilkes of OTCToolbox (right) and Andy Tisman of IQVIA Consumer Health (left)
Thursday 27 February 2020
Presents
8
www.OTCToolbox.com
2020AWARDSCONSUMER HEALTHCARE
INDUSTRY AWARDS
The Essential Business Development Resource
Premium News ServiceKeep up-to-date with the latest news, views and ideas with the OTCToolbox Premium News Service. You can read our basic news stories free of charge but access to the Premium News Stories – in-depth and authoritative coverage – is only available as part of an Annual Subscription.
New Ideas Better WaysRead how innovation can boost all aspects of your business in the OTCToolboxInnovations magazine
Transactions DatabaseResearch acquisitions, licensing agreements and other deals using this searchable online database
OTC Deal Trends Briefi ng
OTC Company Strategies Report
News Extras
Unlimited access to all of our publications
Subscribe to OTCToolbox
What will your subscription provide?
The OTCToolbox website provides online publications that enable business developers and innovators in the consumer healthcare/OTC industry worldwide make well-informed decisions.
Taking out an Annual Subscription to OTCToolboxwill help you and your company understand the developments and ideas that really matter.
Helping you and your company make well-informed decisionswww.OTCToolbox.com
Toolbox A4 leaflet 2020.indd 1Toolbox A4 leaflet 2020.indd 1 17/02/2020 16:0717/02/2020 16:07
